FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020160332> ?p ?o ?g. }

• W2020160332 endingPage "1339" @default.
• W2020160332 startingPage "1332" @default.
• W2020160332 abstract "Thiazolidinediones (TZDs) are a new class of antidiabetic drugs that have also been shown to possess antitumoral properties in different human cancers. TZDs bind and activate the peroxisome proliferator-activated receptor (PPAR)-gamma, which is a nuclear receptor acting as a transcription factor in several tissues. In the present study, we evaluated PPARgamma mRNA and protein expression in tissue samples of human adrenocortical carcinomas (ACCs), normal adrenal glands, and the human ACC cell line H295R. PPARgamma mRNA was expressed in six of eight ACC, two of three normal adrenal glands and the H295R cells. These results were confirmed by immunohistochemistry. PPARgamma transcriptional activity in H295R cells, monitored by a reporter gene assay, was induced 2- to 3-fold by TZDs, such as rosiglitazone (RGZ) and pioglitazone, whereas in PPARgamma-transfected cells RGZ alone or RGZ plus 9-cis retinoic acid further increased reporter activity. TZDs inhibited both the proliferation and invasiveness of H295R cells in a dose-dependent manner. Thymidine incorporation was reduced by about 60% by 20 mum of both TZDs. Cotreatment with the retinoic X receptor ligand 9-cis retinoic acid had an additive effect. TZDs increased the number of cells in the G(0)/G(1) phase and decreased them in the S phase. Western blot analysis showed that TZDs increased the expression of the cell cycle inhibitors p21 and p27 and reduced the expression of cyclin D1. Twenty micromoles of RGZ and pioglitazone reduced H295R invasiveness through Matrigel by about 85%. Zymography and ELISA tests showed that TZD inhibited metalloproteinase-2 secretion by H295R cells in a dose-dependent manner. These data suggest that TZDs reduce the malignant potential of the H295R ACC cell line and, therefore, might potentially constitute a novel tool in the medical treatment of human ACCs." @default.
• W2020160332 created "2016-06-24" @default.
• W2020160332 creator A5001019086 @default.
• W2020160332 creator A5001847367 @default.
• W2020160332 creator A5007458013 @default.
• W2020160332 creator A5027938455 @default.
• W2020160332 creator A5032995631 @default.
• W2020160332 creator A5049128949 @default.
• W2020160332 creator A5050902164 @default.
• W2020160332 creator A5054849636 @default.
• W2020160332 creator A5066978573 @default.
• W2020160332 date "2005-03-01" @default.
• W2020160332 modified "2023-09-27" @default.
• W2020160332 title "Thiazolidinediones Inhibit Growth and Invasiveness of the Human Adrenocortical Cancer Cell Line H295R" @default.
• W2020160332 cites W1556540426 @default.
• W2020160332 cites W1670226482 @default.
• W2020160332 cites W1918439017 @default.
• W2020160332 cites W1938617858 @default.
• W2020160332 cites W1966598111 @default.
• W2020160332 cites W1966845502 @default.
• W2020160332 cites W1966861485 @default.
• W2020160332 cites W1979761686 @default.
• W2020160332 cites W1983128420 @default.
• W2020160332 cites W1993342645 @default.
• W2020160332 cites W1994908701 @default.
• W2020160332 cites W2003238497 @default.
• W2020160332 cites W2006340844 @default.
• W2020160332 cites W2006647733 @default.
• W2020160332 cites W2026435298 @default.
• W2020160332 cites W2032368255 @default.
• W2020160332 cites W2046833545 @default.
• W2020160332 cites W2047982128 @default.
• W2020160332 cites W2049509335 @default.
• W2020160332 cites W2057254600 @default.
• W2020160332 cites W2059841926 @default.
• W2020160332 cites W2063065419 @default.
• W2020160332 cites W2064974844 @default.
• W2020160332 cites W2068065285 @default.
• W2020160332 cites W2075542566 @default.
• W2020160332 cites W2077477468 @default.
• W2020160332 cites W2089143862 @default.
• W2020160332 cites W2091321756 @default.
• W2020160332 cites W2091480567 @default.
• W2020160332 cites W2094646101 @default.
• W2020160332 cites W2095310757 @default.
• W2020160332 cites W2097794242 @default.
• W2020160332 cites W2100837269 @default.
• W2020160332 cites W2107752044 @default.
• W2020160332 cites W2115425140 @default.
• W2020160332 cites W2118973833 @default.
• W2020160332 cites W2134812217 @default.
• W2020160332 cites W2144589852 @default.
• W2020160332 cites W2147326561 @default.
• W2020160332 cites W2158028016 @default.
• W2020160332 cites W2163679869 @default.
• W2020160332 cites W2166245417 @default.
• W2020160332 doi "https://doi.org/10.1210/jc.2004-0978" @default.
• W2020160332 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15585569" @default.
• W2020160332 hasPublicationYear "2005" @default.
• W2020160332 type Work @default.
• W2020160332 sameAs 2020160332 @default.
• W2020160332 citedByCount "69" @default.
• W2020160332 countsByYear W20201603322012 @default.
• W2020160332 countsByYear W20201603322013 @default.
• W2020160332 countsByYear W20201603322014 @default.
• W2020160332 countsByYear W20201603322015 @default.
• W2020160332 countsByYear W20201603322016 @default.
• W2020160332 countsByYear W20201603322017 @default.
• W2020160332 countsByYear W20201603322018 @default.
• W2020160332 countsByYear W20201603322019 @default.
• W2020160332 countsByYear W20201603322020 @default.
• W2020160332 countsByYear W20201603322021 @default.
• W2020160332 countsByYear W20201603322022 @default.
• W2020160332 countsByYear W20201603322023 @default.
• W2020160332 crossrefType "journal-article" @default.
• W2020160332 hasAuthorship W2020160332A5001019086 @default.
• W2020160332 hasAuthorship W2020160332A5001847367 @default.
• W2020160332 hasAuthorship W2020160332A5007458013 @default.
• W2020160332 hasAuthorship W2020160332A5027938455 @default.
• W2020160332 hasAuthorship W2020160332A5032995631 @default.
• W2020160332 hasAuthorship W2020160332A5049128949 @default.
• W2020160332 hasAuthorship W2020160332A5050902164 @default.
• W2020160332 hasAuthorship W2020160332A5054849636 @default.
• W2020160332 hasAuthorship W2020160332A5066978573 @default.
• W2020160332 hasBestOaLocation W20201603321 @default.
• W2020160332 hasConcept C126322002 @default.
• W2020160332 hasConcept C134018914 @default.
• W2020160332 hasConcept C170493617 @default.
• W2020160332 hasConcept C185592680 @default.
• W2020160332 hasConcept C187345961 @default.
• W2020160332 hasConcept C2776923340 @default.
• W2020160332 hasConcept C2777180221 @default.
• W2020160332 hasConcept C2778384471 @default.
• W2020160332 hasConcept C2780152017 @default.
• W2020160332 hasConcept C2781121885 @default.
• W2020160332 hasConcept C54355233 @default.
• W2020160332 hasConcept C55493867 @default.
• W2020160332 hasConcept C555293320 @default.

• next